Year Founded
2014
Ownership
Private
Employees
~10
Therapeutic Areas
OncologyImmunology
Stage
Phase 1
Modalities
CAR T cell therapy (CAR-T)

iCell Gene Therapeutics General Information

Positive Phase 1 results for BCMA-CD19 compound CAR in SLE/LN patients showing complete humoral reset and long-term medication-free remission. All patients who received target dose (12/13) were negative for autoantibodies at 3 months, with follow-up to 46 months. Well tolerated with mild CRS (no CRS >1).

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Stony Brook, New York
United States

Drug Pipeline

BCMA-CD19 compound CAR
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to iCell Gene Therapeutics's pipeline data

Book a demo

Key Partnerships

No partnerships listed

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

iCell Gene Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view iCell Gene Therapeutics's complete valuation and funding history, request access »